Immunogenicity and safety of heterologous boost immunization with PastoCovac Plus against COVID-19 in ChAdOx1-S or BBIBP-CorV primed individuals

PLoS Pathogens, Год журнала: 2023, Номер 19(11), С. e1011744 - e1011744

Опубликована: Ноя. 1, 2023

Background This study aimed at evaluation and comparison of PastoCovac Plus protein-subunit vaccine in parallel with ChAdOx1-S (AstraZeneca) BBIBP-CorV (Sinopharm) primarily vaccinated volunteers two doses or BBIBP-CorV. Materials methods 194 enrolled the who were previously primed 2 vaccines. They divided into heterologous regimens receiving a third dose Plus, homologous groups ChAdOx1-S. Serum samples obtained just before 4 weeks after booster dose. Anti-spike IgG neutralizing antibodies quantified conventional live-virus neutralization titer, (cVNT50) assay was done against Omicron BA.5 variant. Moreover, adverse events data recorded doses. Results ChAdOx1-S/PastoCovac group reached 73.0 units increase anti-Spike rise compared to ChAdOx1-S/ ( P : 0.016). No significant difference observed between regarding antibody 0.256), indicating equivalency both types. Adjusting for baseline titers, BBIBP-CorV/PastoCovac showed 135.2 <0.0001) IgG, 3.1 0.008) unit mean group. Adjustment COVID-19 history, age, underlying diseases, titers increased odds fourfold (OR: 1.9; 0.199) BBIBP CorV 37.3; < 0.0001) their corresponding arms. The rise, adjustment same variables, 2.4 0.610) 5.4 0.286) groups. All types had potency neutralize variant no difference. highest rate event incidence Conclusions application individuals successfully specific antibodies’ levels without any serious events. could be administrated regimen effectively boost humoral immune responses.

Язык: Английский

---

Long-term assessment of anti-SARS-CoV-2 antibody levels post-pandemic: Tracking the dynamics after two, three, and four COVID-19 vaccine doses

Journal of Infection and Public Health, Год журнала: 2025, Номер 18(3), С. 102676 - 102676

Опубликована: Янв. 19, 2025

Given the limited available data about to number of vaccine doses administered over an extended time in Iran, immune status vaccinated individuals and any potential disparities this regard among those who received different numbers remain unknown. Therefore, study aimed assess humoral immunity COVID-19 vaccines Iran. This was conducted from February, 2022 December 2023 including 605 subjects. The durability anti-spike, anti-nucleocapsid (NCP), neutralizing antibody, interferon-γ (IFN-γ) evaluated at least 6 months after last vaccination, as well 60 120 days it, two or three vaccine. Furthermore, evaluation cellular response performed before fourth dose (second booster) 21 thereafter. 3-dose group showed significantly higher levels antibodies, IFN-γ compared 2-dose group. Both groups experienced a slight decrease dynamic SARS-CoV-2 Abs, though associated remained within positive range. After receiving PastoCovac, most participants had high IFN-γ, regardless type three-dose regimen they previously received. average antibody titer decreased dose, but relatively stable during follow-up period. found that level anti-SARS-CoV-2 antibodies their durability, were still range long-term follow-up. PastoCovac enhanced responses could be recommended booster for with

Язык: Английский

---

A landscape on disorders following different COVID-19 vaccination: a systematic review of Iranian case reports

European journal of medical research, Год журнала: 2023, Номер 28(1)

Опубликована: Ноя. 26, 2023

Abstract There have been massive studies to develop an effective vaccine against SARS-CoV-2 which fortunately led manage the recent pandemic, COVID-19. According quite rapidly developed vaccines in a fast window time, large investigations assess probable vaccine-related adverse events are crucially required. COVID-19 available of different platforms and primary clinical trials results presented acceptable safety profile approved vaccines. Nevertheless, long-term assessment or rare conditions need be investigated. The present systematic review, aimed at classification unsolicited Iranian population through data collection published case report studies. related reports were explored via PubMed, Web Science Google scholar according up 14 th Dec, 2022 using PRISMA guideline. Out 437 studies, relevant fully investigated totally 40 including 64 with new onset problem post-vaccination. cases then classified various items, such as type event reported studied included BBIBP-CorV, ChAdOx1-S, Sputnik V COVAXIN. showed that 8 categories, cutaneous involvements 43.7% ( n = 28), neurologic problems 16), blood/vessel involvement 6), cardiovascular 5), ocular disorders 4), liver disorder/failure 2), graft rejection 2) one metabolic disorder. Notably, almost 60% had no comorbidities. Moreover, obtained revealed nearly half incidences occurred after first dose injection median duration improvement symptom was 10 days (range: 2–120). In addition, 73% all either significantly improved recovered. Liver failure following ChAdOx1-S vaccination most serious death two individuals medical history. Although advantages is undoubtedly significant, history disease, comorbidities immunodeficiency should vaccinated utmost caution. This study provides comprehensive overview implications possible considered further strategies. there might bias regarding potential under-reporting missing study. not proven direct outcomes could immune response over stimulation, people medium/high risk monitored getting any platforms. achieved by carefull attention subjects ‘ also consulting healthcare providers before vaccination.

Язык: Английский

---

Lessons from COVID-19 Pandemic: A Successful Policy and Practice by Pasteur Institute of Iran

Deleted Journal, Год журнала: 2024, Номер 28(1), С. 1 - 7

Опубликована: Янв. 1, 2024

The present study aims to provide an insight the comprehensive efforts of PII regarding COVID-19 management, research, achievements, and vaccine production, though there are many challenges.The relevant literature review was investigated through national international database also reports from related research departments.Six strategies were taken by manage pandemic COVID-19.While this has been hopefully controlled, SARS-CoV-2 could still be a potential threat.Therefore, data management updated studies, as well longterm safety efficacy vaccines on agenda.

Язык: Английский

---

Long-term rheumatoid manifestations as a consequence of COVID-19 and/or vaccination: A case report after a 2-year follow-up

Heliyon, Год журнала: 2024, Номер 10(3), С. e24982 - e24982

Опубликована: Янв. 18, 2024

COVID-19 is now established as a multi-organ involvement disease with broad range of manifestations. Identification post-acute incidence critical according to increasing number late symptoms reports. Hereby, we report case past history who presented different manifestations including osteoarticular and neurological within long-term follow-up. The organs initiated lately after primary vaccinations (with inactivated vaccine) lasted few months without any pre-existing medical condition. However, upon the completion vaccine schedule receiving protein subunit vaccine, PastoCovac Plus, booster, improved substantially resolved, though in reinfection episode partial, reoccurrence was recorded. This presentation can be challenging issue owing fact that majority global population are vaccinated also experience this era sometimes differentiation between consequences virus post or vaccination side effects difficult.

Язык: Английский

---

The impact of ABO blood types on humoral immunity responses and antibody persistency after different COVID‐19 vaccine regimens

Journal of Medical Virology, Год журнала: 2024, Номер 96(2)

Опубликована: Фев. 1, 2024

Abstract This study evaluated the possible effects of blood types on coronavirus disease (COVID‐19) vaccine immunogenicity and antibody (Ab) persistency. Five different vaccinated groups against COVID‐19 were investigated at Pasteur Institute Iran from April 2021 to December 2022. Anti‐Spike IgG neutralizing Ab rise tracked Day 21 as well humoral immune persistency assessment 180 after booster shots. Late adverse events up 6 months dose collected. The results showed that type A, led a significantly higher anti‐Spike in AstraZeneca primed recipients comparison with Sinopharm ones heterologous regimens ( p : 0.019). Furthermore, O was great co‐effector homologous regarding (0.013). In addition, better group whereas A had best effect durability same group. What is more, Rh‐positive individuals + PastoCovac Plus rate = 0.001). Neutralizing also induced than cases. present potential impact A/O responses It proposed could increase individuals. Moreover, might be recipients.

Язык: Английский

---

Comparative assessment of a COVID-19 vaccine after technology transfer to Iran from critical quality attributes to clinical and immunogenicity aspects

Scientific Reports, Год журнала: 2024, Номер 14(1)

Опубликована: Ноя. 5, 2024

During COVID-19 pandemic, international pharmaceutical companies put effort to build global manufacturing networks for vaccines. Soberana Plus vaccine, a recombinant protein based vaccine (RBD dimer), with the trade name of PastoCovac in Iran, is on subunit platform Cuba and completed preclinical toxicological assessments. This study aimed at presenting steps technology transfer from Iran. provides first practical comparability results Iran ensure quality, safety efficacy against after successful Cuba. was transferred formulation stage. The assessment active ingredient (API) achieved through physicochemical clinical data collection tests assure if there any adverse impact vaccination results. In order assess quality product transfer, we sought different properties including regulatory features, potency stability as well its immunogenicity safety. Following evaluation attributes (CQAs) standard protocols, showed that two vaccines are highly similar comparable, no considerable effect or profiles. CQAs were all acceptance limits terms also confirmed significant differences between regarding reinfection (P = 0.199) breakthrough 0.176). Furthermore, level anti-spike neutralizing antibodies both groups not significantly indicating equality performance According this study, an acceptable acceptant pre post transfer.

Язык: Английский

---

Potential Protectivity of a Conjugated COVID-19 Vaccine against Tetanus

Vaccines, Год журнала: 2024, Номер 12(3), С. 243 - 243

Опубликована: Фев. 26, 2024

PastoCovac is a subunit protein vaccine against COVID-19 which contains the tetanus toxoid as carrier conjugated to SARS-CoV-2 RBD. The primary goal of application was elicit stronger specific response in individuals. However, conjugate vaccines have potency generate anticarrier antibodies addition target antigen. Therefore, present study aimed evaluate humoral immune induction tetanus. Six groups individuals, including those who received one, two, or three doses vaccine, Td and also controls other (except PastoCovac), were investigated. anti-tetanus IgG assessed by an ELISA assay all vaccinated groups. antibody persistency group one dose on day 60, 90, 180 after last injection. titer recipients positive, though additional led significant rise (p = 0.003). Notably, comparison mean between one/two showed that before injection not significant. Although decreased lower level than 21, it still estimated be highly positive Eventually, none presented side-effects during follow-up. current data indicate COVID-19, PastoCovac, could induce responses tetanus, can persist for at least 6 months. Combination formulae containing TT DT carriers considered instead and/or boosters adults if they are indicated.

Язык: Английский

---

Assessment of COVID‐19 Vaccine Impact on Women’s Menstrual Health within an 18‐Month Follow‐Up

Obstetrics and Gynecology International, Год журнала: 2024, Номер 2024(1)

Опубликована: Янв. 1, 2024

Considering menstruation as a crucial factor in females' health and fertility, any that could change its cycle is important. This study was conducted from April 2021 to October 2022 on females who got 3 doses of vaccines against SARS-CoV-2 through different platforms. The participants were requested provide the trained experts with changes regarding menstrual cycles after each dose vaccine up 6 months booster shots. disturbances related identified by adverse events committee find possible associations applied vaccines. Of 308 women participated until end study, 22 (7.1%) complained about at least one abnormality their patterns. most common disturbance metrorrhagia 10 (48%) incidences followed menorrhagia (24.2%). Notably, complaints persistent 59% patients. In addition, 14 studied cases developed COVID-19 infection disorders. these cases, also play role persistence postvaccine disturbances. vaccination affect no remarkable previous medical history. More longitudinal studies are required this issue.

Язык: Английский

---

Maintenance of Long-Term Effective Humoral Immune Response in Patients with COVID-19 with Homologous or Heterologous Booster Vaccines: A Retrospective Study

Viral Immunology, Год журнала: 2024, Номер 37(10), С. 480 - 488

Опубликована: Дек. 1, 2024

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and first identified in Wuhan, China, December 2019, has led to global efforts vaccination mitigate rising morbidity mortality, with vaccines proving crucial controlling the pandemic. This study evaluated humoral responses inactivated virus vaccine Sinopharm or Koxing Kerlafor, protein subunit ZF001, adenoviral vector Convidecia after 18 months of heterologous homologous booster patients previous SARS-CoV-2 infection healthy individuals. We discovered that who had recovered from then received a third dose (booster) exhibited durable immunity. Furthermore, induced higher neutralizing antibody compared booster. These findings offer valuable insights into efficacy different COVID-19 strategies following immunization.

Язык: Английский

---